Novartis AG (NVS) stock prices updated...
 

Novartis AG stock price

Novartis AG latest news:


  • 11/13/2017 10:00:00

    Novartis launches heart drug counter-offensive

    ZURICH, Nov 13 (Reuters) - Novartis plans to plow through doubts over its canakinumab drug by asking regulators this year to approve the medicine as a treatment for a group of heart attack survivors that the Swiss drugmaker says is most likely to benefit.

  • 11/10/2017 15:30:23

    Novartis posts eye drug data amid play for Eylea's turf

    Novartis's bid to move in on Bayer's and Regeneron's eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new RTH258 drug showed less disease activity than those on its rivals' drug Eylea.

  • 10/30/2017 00:18:57

    BRIEF-Advanced Accelerator announces $3.9 bln all cash proposed tender offer by Novartis

    Advanced Accelerator Applications Sa(AAAP). * Advanced accelerator applications announces $3.9 billion all cash proposed tender offer by Novartis. * Novartis will make cash tender offer to acquire all outstanding shares of co, including ADS, for $41 a share and $82 per ADS​. * Deal ‍represents 47 percent premium to 30 volume-weighted trading days prior to unaffected share price on nasdaq on Sept 27.

  • 10/27/2017 16:08:20

    BRIEF-Ophthotech recieves termination notice from Novartis Pharma

    * Ophthotech-On oct 24, co received from Novartis Pharma notice terminating Licensing & Commercialization Agreement between parties dated May 19, 2014 Source text : (http://bit.ly/2gPty5O) Further company coverage:

  • 10/24/2017 01:33:00

    Novartis boosts third-quarter profit, pushes Alcon decision to 2019

    Novartis's third-quarter core net income rose 4 percent at constant currencies, beating expectations.

  • 10/24/2017 00:20:10

    BRIEF-Novartis CEO: Alcon spinoff 'probably direction we are headed' - CNBC

    * Ceo says wants to time alcon exit when market is strong, expects strong market to continue - cnbc

  • 10/24/2017 00:16:55

    BRIEF-Novartis CEO: Novartis shareholders would get Alcon shares in listing

    * CEO Joe Jimenez says expects U.S. price pressure on generics business to remain

  • 09/05/2017 15:48:38

    Narasimhan to Replace Jimenez as Novartis (NVS) CEO in 2018

    Novartis AG NVS announced that its Chief Executive Officer CEO Joseph Jimenez will step down from his position in 2018 Vasant Narasimhan M D Global Head of Drug Development and Chief Medical Officer will replace him effective Feb 1 2018 Narasimhan is a member of the Executive

  • 09/05/2017 15:31:12

    BRIEF-Novartis Pharma reports a 6.6 percent passive stake in Xoma Corp as of August 24, 2017

    * Novartis Pharma AG reports a 6.6 percent passive stake in Xoma Corp as of august 24, 2017 - SEC filing‍​ Source text for Eikon: (http://bit.ly/2gEet2Y) Further company coverage:

  • 09/04/2017 01:46:59

    Novartis CEO Jimenez to step down early next year

    Novartis says CEO Joseph Jimenez will step down early next year and be replaced by fellow American Vasant Narasimhan, a longtime manager with the Swiss pharmaceutical company

  • 09/04/2017 00:08:22

    Novartis's Jimenez stepping down, Narasimhan named new CEO

    ZURICH (Reuters) - Novartis Chief Executive Joseph Jimenez will retire in 2018, with chief drug developer Vasant Narasimhan taking over as CEO starting in February, the Swiss drugmaker said on Monday.

  • 08/30/2017 14:49:04

    Why Novatis' $475K CAR-T Cancer Treatment Is Actually Cheap

    The cancer treatment industry is celebrating a massive victory on Wednesday as Novartis NVS received approval for its innovative new lymphoblastic leukemia treatment making it the first approved CAR T therapy in the world After achieving unprecedented results in patients with this deadly

  • 08/30/2017 09:48:36

    BRIEF-Novartis receives FDA approval for CAR-T cell therapy Kymriah

    * Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice Source text for Eikon: Further company coverage:

  • 08/30/2017 09:29:54

    Biotech stocks rally, ETF on track for third straight daily gain

    Biotechnology stocks rallied on Wednesday, with one of the biggest exchange-traded funds dedicated to the sector on track for its third straight daily advance. The iShares Nasdaq Biotechnology ETF gained 1.3%, bringing its week-to-date rise to 3.6%. Among the biggest gainers in the sector, Gilead Sciences Inc. popped 5.6%, bringing its gain over the past three months to 23.7%. The stock is on track for its largest percentage gain since November, as well as its highest close since September 2016. Separately, Incyte Corp. added 4.5% while BioMarin Pharmaceutical Inc. advanced 4.8%. Biogen Inc. gained 2.4% while Regeneron Pharmaceuticals Inc. was up 2%. On the downside within the pharmaceutical sector, U.S.-listed shares of Novartis AG were down 1%. The company's CAR-T cell therapy was approved by the Food and Drug Administration on Wednesday, making it the first gene therapy to be available in the U.S. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 08/30/2017 09:21:49

    Novartis AG's CAR-T cell therapy for leukemia approved by FDA in 'historic action'; price to be based on outcomes

    Novartis AG's CAR-T cell therapy was approved by the Food and Drug Administration on Wednesday, making it the first gene therapy to be available in the U.S. Novartis' Kymriah was approved for young people up to age 25 with a form of acute lymphoblastic leukemia. CAR-T, or chimeric antigen receptor T-cell therapy, uses a patient's immune T-cells and re-engineers them to better fight cancer. As such, each dose of Kymriah is customized to the individual patient's T-cells through genetic modification. Novartis said on Wednesday that it will work with the Centers for Medicare and Medicaid Services so medicine prices can be "based on the clinical outcomes achieved, which would eliminate inefficiencies from the health care system." For Kymriah, Novartis is also working with CMS "to allow for payment only when pediatric and young adult ALL patients respond to Kymriah by the end of the first month." Novartis did not give any specifics as to what the price range might be. Even before Novartis' Kymriah was approved, there was concern about pricing of the new therapy, given that new therapies are typically priced based on level of innovation and cancer is a particularly expensive area. On Wednesday, the FDA also expanded approval of Roche's Genentech's rheumatoid arthritis drug Actemra to treat CAR-T cell-induced cytokine release syndrome, which consists of high fever and flu-like symptoms and can be life-threatening; nearly 70% of patients had CRS completely resolved in two weeks using one or two doses of Actemra, the FDA said. Kite Pharma, which is also working in the CAR-T space, has also been racing to gain FDA approval; the biotech's $11 billion acquisition by Gilead Sciences Inc. was reported earlier this week. Gilead shares surged 5.5% in extremely heavy midday trade. Novartis shares declined 1% in heavy midday trade. Novartis shares have risen 2.8% over the last three months, compared with a 1.6% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 08/30/2017 09:06:10

    Novartis gene therapy for leukemia wins U.S. approval

    Aug 30 (Reuters) - The U.S. Food and Drug Administration (FDA) on Wednesday approved Novartis AG's keenly anticipated leukemia treatment, marking the first gene therapy approval in the United States.

  • 08/27/2017 11:18:33

    UPDATE 1-Novartis hopeful for novel heart drug, despite 'modest' benefit

    * Novartis plans Q4 filing with regulators (Adds analyst comment on pricing)

  • 08/25/2017 09:45:36

    Novartis (NVS) Receives EC Approval for Breast Cancer Drug

    Novartis AG NVS announced that the European Commission EC has approved breast cancer drug Kisqali ribociclib The EC approved the drug in combination with an aromatase inhibitor for treatment of postmenopausal women with hormone receptor positive human epidermal growth factor receptor

  • 08/24/2017 00:56:15

    Novartis picks retail expert for new role of digital chief

    LONDON, Aug 24 (Reuters) - Novartis has appointed a senior retail expert to the new post of chief digital officer, following a similar move by GlaxoSmithKline last month, underscoring how drugmakers are grappling with the impact of new technology.

  • More trends:

    Novo Nordisk A/SNVO | NOW Inc.DNOW | NQ Mobile Inc.NQ | NRG EnergyNRG | NRG YieldNYLD | NRG YieldNYLD.A | NTT DOCOMODCM | Nu Skin EnterprisesNUS | Nucor CorporationNUE | Nustar Energy L.P.NS |